ALL WALES MEDICINES STRATEGY GROUP

WEDNESDAY, 15TH OCTOBER 2008 COMMENCING 10.30 AM
(UNTIL 4.30 PM APPROX)
AT THE ANGEL HOTEL, ABERGAVENNY

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal report)
5. Minutes of previous meeting
   - Matters arising
6. Appraisal 1 – stiripentol (Diacomit®)
   In conjunction with clobazam and valproate as adjunctive therapy of refractory
   generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in
   infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled
   with clobazam and valproate
7. Appraisal 2 – rufinamide (Inovelon®)
   For treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as
   adjunctive therapy in patients four years and older
8. Appraisal 3 – raltegravir (Isentress®)
   In combination with other antiretroviral medicinal products agents for the treatment
   of Human Immunodeficiency Virus (HIV-1) infection in treatment-experienced adult
   patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
9. Appraisal 4 – icatibant (Firazyr®)
   Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults
   with C1-esterase-inhibitor deficiency
10. Appraisal 5 – abacavir/lamivudine (Kivexa®)
    Antiretroviral combination therapy for the treatment of human immunodeficiency
    virus (HIV) infection in adults and adolescents from 12 years of age
11. Appraisal 6 – teriparatide (Forsteo®)
    To increase bone mass in men with primary or hypogonadal osteoporosis who are
    at high risk from fracture
12. Update on NHS Industry Forum (verbal report)
13. Update on AWPAG (verbal report)
    - Unlicensed oral liquid medicines
14. Update on WAPSU (verbal report)

Date of the next AWMSG meeting is Wednesday, 10th December 2008 at
The Angel Hotel, Abergavenny commencing 10.30 am